June 2008 Volume 26 Number 6, pp 589 - 714
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0dXt0EC
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0aAP0EA
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BRQi0Eg
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BkE0EA
=====================================================================
Want to eliminate background in your immunoprecipitations?
Reduce non-specific binding and cut your protocol to only 40 min with Dynabeads(R).
Don't get left behind - Check out our introductory offer today at:
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bplm0Eh
=====================================================================
=====================================================================
The Source Event - London, 26/09/2008
Now in its 2nd successful year, The Source Event is a dedicated science
career fair from Naturejobs, combining a dynamic exhibition with
conference and workshop sessions. The programme is divided into 3
streams: Graduate, Post Doc and Non-traditional careers. Exhibitors
include a wide range of employers, recruitment agencies and governmental
institutions.
Register now at: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwBw0EI
=====================================================================
=====================================================================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BpT40EM
=====================================================================
=====================================================================
FREE TRIAL AVAILABLE -- SciBX: Science-Business eXchange
To keep up with emerging business-critical science you can read the top
40 journals - or you can read the weekly SciBX analysis. The SciBX team
evaluates over 400 papers each week and distills the must-read science.
To find out which papers made it into SciBX this week,
sign up for a FREE TRIAL at http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Burw0E3
=====================================================================
=====================================================================
What are top biotech and pharma executives looking for today?
Find out now.
Read Nature's semi-annual Licensing Executive Profiles in the June issues of
Nature Biotechnology and Nature Reviews Drug Discovery, or online at
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyg0Ev
=====================================================================
----------------------
EDITORIAL
----------------------
What you don't know will hurt you p589
The heparin scare highlights the need not only for more effective systems of adverse event reporting and product tracking, but also for drug makers to tighten scrutiny of their suppliers.
doi:10.1038/nbt0608-589
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyh0Ew
----------------------
NEWS
----------------------
HIV vaccine developers battle on, despite high-profile failures pp591 - 592
Heidi Ledford
doi:10.1038/nbt0608-591
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyi0Ex
FDA balks at Myozyme scale-up p592
George Mack
doi:10.1038/nbt0608-592
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyj0Ey
Millennium ends Takeda's US shopping spree pp593 - 595
Douglas Sipp
doi:10.1038/nbt0608-593
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyk0Ez
GSK moves on Sirtris p595
Douglas Sipp
doi:10.1038/nbt0608-595
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyl0E1
Agency on hiring spree p596
Emily Waltz
doi:10.1038/nbt0608-596a
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwym0E2
University patents probed p596
Emily Waltz
doi:10.1038/nbt0608-596b
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyn0E3
Industry welcomes Genetic Information Nondiscrimination Act pp596 - 597
Malorye Allison
doi:10.1038/nbt0608-596c
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyo0E4
Patent reform stalls p597
Amy Coombs
doi:10.1038/nbt0608-597a
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyp0E5
In silico vaccine p597
Henry Nicholls
doi:10.1038/nbt0608-597b
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyq0E6
FDA scrutinizes human stem cell therapies pp598 - 599
Jeffrey L Fox
doi:10.1038/nbt0608-598
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyr0E7
Canada charts biologics path p599
Hannah Hoag
doi:10.1038/nbt0608-599a
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwys0E8
FDA gets personal p599
Henry Nicholls
doi:10.1038/nbt0608-599b
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyt0EA
Profile: Fred Kavli p600
Fred Kavli is a visionary philanthropist who began selling wood briquettes in wartime Norway and is now investing his fortune in keeping blue-sky research alive.
Joe Alper
doi:10.1038/nbt0608-600
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyu0EB
DATA PAGE
Partnerships remain buoyant p602
Stacy Lawrence
doi:10.1038/nbt0608-602
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyv0EC
NEWS FEATURE
When animal rights turns ugly pp603 - 605
Despite tightened legislation against animal rights extremism, activists are increasing attacks on academics and researchers in big pharma. How much of a threat do they pose to researchers working in biotech? Brady Huggett investigates.
doi:10.1038/nbt0608-603
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyw0ED
=====================================================================
Are you looking for a partner?
Let us help you select suitable Antibody interaction partners by using
the Attana A100(R) C-Fast system: label-free, molecular interaction analysis in real time.
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bpln0Ei
=====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Leveraging your biotech intellectual property pp607 - 609
Biotech companies can extract unexpected value from their patent portfolios to remove roadblocks on the path to commercialization and success.
Michael B Harlin and Kevin A O'Connor
doi:10.1038/bioe.2008.5
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyx0EE
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Predicting disease outcomes in the clinic pp611 - 612
Mark A Jensen
doi:10.1038/nbt0608-611
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyy0EF
Response to Predicting disease outcomes in the clinic pp612 - 613
doi:10.1038/nbt0608-612
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwyz0EG
Caring about microenvironments pp613 - 614
Cameron Lutton and Ben Goss
doi:10.1038/nbt0608-613
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy10E2
Fallout from flip-flops pp614 - 615
Paul Froese
doi:10.1038/nbt0608-614
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy20E3
Forest biotech and climate change pp615 - 617
Trevor M Fenning, Christian Walter and Kevan M A Gartland
doi:10.1038/nbt0608-615
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy30E4
A cautionary note on pathogen-derived sequences pp617 - 619
Alessandra Lucioli et al.
doi:10.1038/nbt0608-617
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy40E5
COMMENTARY
The FDA and safety - beyond the heparin crisis pp621 - 623
The discovery of a contaminant in batches of heparin throws into stark relief the difficulties, not only for the US Food and Drug Administration, but also for international regulatory agencies, to ensure the safety and quality of active pharmaceutical ingredients.
Cato T Laurencin and Lakshmi Nair
doi:10.1038/nbt0608-621
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy50E6
Canaries, coal mines and the drug supply pp624 - 626
The heparin safety crisis sends a strong signal that urgent changes in regulatory and manufacturing oversight are needed to ensure the safety of the global drug supply.
Jeffrey M Leiden
doi:10.1038/nbt0608-624
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy60E7
=====================================================================
This alert is sponsored by Qlucore
Efficiently analyze large data sets.
Intuitive methods help you find patterns and structure with a few mouse clicks. Immediate response is guaranteed for all data sets (example: gene expression data) up to size 500 x 100 000 when you use a normal PC.
Download free evaluation at http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BuiN0EE
=====================================================================
----------------------
FEATURE
----------------------
Brazilian health biotech[mdash]fostering crosstalk between public and private sectors pp627 - 644
Brazil boasts world-class biomedical science, but tension between the public and private sectors hinders progress in health biotech innovation.
Rahim Rezaie et al.
doi:10.1038/nbt0608-627
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy70E8
PATENTS
Patent protection and access to genetic resources pp645 - 647
Developing countries and patent offices have shown differing approaches to patent specification disclosure requirements and benefit sharing.
Itsuki Shimbo, Yoko Ito and Koichi Sumikura
doi:10.1038/nbt0608-645
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Bwy80EA
Recent patent applications in biological imaging p648
doi:10.1038/nbt0608-648
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzA0EK
----------------------
NEWS AND VIEWS
----------------------
Next-generation sequencing-by-hybridization pp649 - 650
A new hybridization-based technology offers advantages in sequencing genomes for which a reference genome exists.
Paul M Lizardi
doi:10.1038/nbt0608-649
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzB0EL
Targeted mutagenesis in zebrafish pp650 - 651
Directed gene knockout in a vertebrate has been achieved using zinc-finger nucleases.
Ian G Woods and Alexander F Schier
doi:10.1038/nbt0608-650
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzC0EM
Proteases' prime targets revealed pp652 - 653
Mass spectrometry analysis of proteome-derived peptide libraries enables high-throughput determination of protease substrate specificity.
Scott L Diamond and Doron Greenbaum
doi:10.1038/nbt0608-652
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzD0EN
Stable transgenes bear fruit pp653 - 654
Analysis of the transgenic papaya genome sequence suggests that transgenes generally stay put following integration and can achieve stable expression level from generation to generation.
Ajay Kohli and Paul Christou
doi:10.1038/nbt0608-653
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzE0EO
A new path to the cancer epigenome pp655 - 656
A regulator of the spatial organization of chromatin may be a promising target to curb the invasiveness of breast cancer.
Victoria M Richon
doi:10.1038/nbt0608-655
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzF0EP
Research Highlights p657
doi:10.1038/nbt0608-657
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzG0EQ
----------------------
COMPUTATIONAL BIOLOGY
----------------------
REVIEW
The growing scope of applications of genome-scale metabolic reconstructions using Escherichia coli pp659 - 667
Adam M Feist and Bernhard O Palsson
doi:10.1038/nbt1401
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzH0ER
Article: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzI0ES
----------------------
RESEARCH
----------------------
ARTICLES
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events pp669 - 675
Marco Guerrini et al.
doi:10.1038/nbt1407
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzJ0ET
Article: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzK0EU
Rapid genome sequencing with short universal tiling probes pp676 - 684
Arno Pihlak et al.
doi:10.1038/nbt1405
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzL0EV
Article: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzM0EW
Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites pp685 - 694
Oliver Schilling and Christopher M Overall
doi:10.1038/nbt1408
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzN0EX
Article: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzO0EY
LETTERS
Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases pp695 - 701
Xiangdong Meng et al.
doi:10.1038/nbt1398
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzP0EZ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzQ0Ea
Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases pp702 - 708
Yannick Doyon et al.
doi:10.1038/nbt1409
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzR0Eb
Article: http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzS0Ec
ERRATA
Erratum: Tony Conner p709
Jim Kling
doi:10.1038/nbt0608-709a
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzT0Ed
Erratum: Antivirals become a broader enterprise p709
Jeffrey L Fox
doi:10.1038/nbt0608-709b
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzU0Ee
CORRIGENDA
Corrigendum: Direct multiplexed measurement of gene expression with color-coded probe pairs p709
Gary K Geiss et al.
doi:10.1038/nbt0608-709c
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzV0Ef
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Technology transfer and idea commercialization pp711 - 712
Technology transfer professionals work at the interface of science and business to help move discoveries forward for the public good.
Judith Sheft
doi:10.1038/nbt0608-711
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzW0Eg
PEOPLE
People p714
doi:10.1038/nbt0608-714
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BwzX0Eh
=====================================================================
Nature Reviews Microbiology
Poster on Metagenomics
An overview of the technology and applications of Metagenomics
Metagenomics is a powerful tool that can be used to analyze microbial
communities regardless of the ability of member organisms to be cultured
in the laboratory. This technology will likely lead to major advances
in medicine, agriculture, energy production and bioremediation.
Access the Poster FREE online at
www.nature.com/nrmicro/posters/metagenomics
Produced with support from:
The National Science Foundation
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BvIk0EC
The National Academies
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0BvIj0EB
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/elOM0Xztnp0HjC0Zzu0Eb
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
